| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6773720 | TAKEDA PHARMS USA | Mesalazine controlled release oral pharmaceutical compositions |
Jun, 2020
(3 years ago) | |
Lialda is owned by Takeda Pharms Usa.
Lialda contains Mesalamine.
Lialda has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Lialda are:
- US6773720
Lialda was authorised for market use on 16 January, 2007.
Lialda is available in tablet, delayed release;oral dosage forms.
The generics of Lialda are possible to be released after 26 June, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 26, 2023 |
| New Indication(I-640) | Jul 14, 2014 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 16 January, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
How can I launch a generic of LIALDA before it's drug patent expiration?
More Information on Dosage
LIALDA family patents
